[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"implant-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:implant-complication":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,49,80,110,140,175,197,220,248,277,303,325],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100519049","immediate-versus-delayed-loading-of-maxillary-overdenture-implants-100519049",false,"NCT06038487","Immediate Versus Delayed Loading of Maxillary Overdenture Implants","Inclusion Criteria:\n\n1. Males and females must be at least ≥ 21 years of age\n2. Fully edentulous maxilla\n3. The implant site has to be healed for at least 4 months after extraction\n4. Wearing complete dentures deemed adequate\n5. Orthopantomogram available (OPT)\n6. Adequate amount of bone at least at the 2nd premolar position to house at minimum a 3.5 x 10 mm BLX-Roxolid implant\n7. No bone grafting required\n8. Implant IT ≥ 20 N\u002Fcm\n\nExclusion Criteria:\n\n1. Conditions requiring chronic routine prophylactic use of antibiotics\n2. Conditions requiring prolonged use of steroids\n3. History of leukocyte dysfunction and deficiencies\n4. Bleeding disorders\n5. History of neoplastic disease requiring use of radiation or chemotherapy\n6. Metabolic bone disorders\n7. Uncontrolled endocrine disorder\n8. Use of any investigational drug or device within the 30-day period prior to implant surgery\n9. Vaping, Tobacco Chewing or Smoking more than 10 cigarettes a day\n10. Alcoholism or drug abuse\n11. Patient infected with HIV\n12. Condition or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as as history of non-compliance, unreliability.\n13. Local inflammation including untreated periodontitis\n14. Mucosal disease such as erosive lichen planus\n15. History of local irradiation therapy\n16. Osseous lesion\n17. Severe bruxism and clenching habits\n18. Active infection with suppuration or fistula track\n19. Persistent intraoral infection\n20. Lack of primary stability \\\u003C20Ncm. In this instance, the patient must be withdrawn and treated according to the standard protocol.\n21. Inadequate oral hygiene or unmotivated home care.\n22. Bone grafting needed\n23. Inadequate bone volume for implants insertion as measured on the pre-treatment cone beam computed tomography (CBCT).",true,"ALL","21 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of the study is to evaluate the radiographic, clinical and patient-centered outcomes of implant-retained immediately-loaded maxillary complete dentures in comparison to delayed loading approach by primarily evaluating radiographic bone loss of dental implants placed in the maxilla over 36 months",[26],"Implant Complication",[28,29,30,31,32,33,34,35],"Implant Overdenture","Immediate loading","Delayed loading","Maxillary Overdenture","Novaloc Retention System","Guided Implants","Immediate vs Delayed loading","Implant-supported overdenture","RECRUITING","2026-05-19",{"date":39,"type":40},"2026-05-20","ACTUAL",{"date":42,"type":40},"2023-02-01",{"date":44,"type":20},"2028-02-01",{"name":46,"class":47},"Case Western Reserve University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100543426","improvement-of-symptoms-after-removal-of-the-essure-contraceptive-implant-100543426","NCT06355713","Improvement of Symptoms After Removal of the Essure® Contraceptive Implant","Prospective Multicenter Study of the Improvement of Symptoms After Removal of the Essure® Contraceptive Implant","ABLES","* Inclusion Criteria \\* :\n\nESSURE Group:\n\n* woman aged 35 to 75\n* patient with at least one Essure® implant\n* surgical intervention planned because the patient is symptomatic: removal of the Essure® implant(s)\n* planned intervention via vaginal route, laparoscopy, robotic surgery, or Transvaginal natural orifice transluminal endoscopic surgery (VNotes)\n* patient having given free, informed and signed consent\n\nSelection for MRI-PET examination:\n\n* if the answer is \"poor\" or \"bad\" to the first question of the SF-12 pre-operatively\n* no hysterectomy\n* no analgesic treatment, or treatment stopped 48 hours before the examination\n* no psychotropic treatment (anxiolytics, hypnotics (sleeping pills), antidepressants, mood stabilizers, neuroleptics)\n* patient having given free, informed and signed consent\n\nControl group:\n\n* woman aged 35 to 75\n* planned surgical intervention: salpingectomy with or without hysterectomy for benign indication\n* planned intervention via vaginal route, laparoscopy, robotic surgery, or VNotes\n* patient having given free, informed and signed consent\n\nSelection for MRI-PET examination:\n\n* age matching (+\u002F- 5 years) with Essure® patients who have had an MRI-PET\n* matching on surgical technique with Essure® patients who have had an MRI-PET: salpingectomy with or without hysterectomy\n* no analgesic treatment, or treatment stopped 48 hours before the examination\n* no psychotropic treatment (anxiolytics, hypnotics (sleeping pills), antidepressants, mood stabilizers, neuroleptics)\n* patient having given free, informed and signed consent\n\n  * Exclusion Criteria \\* :\n\nESSURE Group:\n\n* asymptomatic patient\n* planned intervention by laparotomy\n* patient potentially exposed to other heavy metals: wearer of metallic orthopedic equipment (hip or knee prosthesis, etc.), wearer of coronary stent, or tubal ligation clip\n* inability to understand the information given\n* persons deprived of liberty by a judicial or administrative decision\n* people undergoing psychiatric care\n* people admitted to a health or social establishment for purposes other than research\n* adults subject to a legal protection measure (guardianship, curatorship)\n* people not affiliated to a social security scheme or beneficiaries of a similar scheme\n* person participating in another interventional research that may interfere with the research\n\nSelection for MRI-PET examination:\n\n* claustrophobia\n* dosimetry of all radiological examinations over the past year not acceptable\n\nControl Group :\n\n* current pregnancy\n* patient with cancer\n* patient who has already had an Essure® implant removed\n* patient potentially exposed to heavy metals: wearer of metallic orthopedic equipment (hip or knee prosthesis, etc.), wearer of coronary stent, or tubal ligation clip\n* planned intervention by laparotomy\n* inability to understand the information given\n* persons deprived of liberty by a judicial or administrative decision\n* people undergoing psychiatric care\n* people admitted to a health or social establishment for purposes other than research\n* adults subject to a legal protection measure (guardianship, curatorship)\n* people not affiliated to a social security scheme or beneficiaries of a similar scheme\n* person participating in another interventional research that may interfere with the research\n\nSelection for MRI-PET examination:\n\n* claustrophobia\n* dosimetry of all radiological examinations over the past year not acceptable","FEMALE","35 Years","75 Years",{"count":61,"type":20},444,[23],"ESSURE® is an implantable medical device for definitive and irreversible sterilization indicated for adult women of childbearing age. These implants are inserted into the fallopian tubes by hysteroscopy. Marketed in 2002, ESSURE® contraceptive implants were withdrawn from the French market in 2017 (and worldwide in 2017 and 2018) following the observation in certain patients of polymorphic and non-specific gynecological and extra-gynecological symptoms. Studies with small numbers and short-term follow-up have shown a significant improvement in these symptoms after implant explantation. This constitutes a real public health problem since according to the report of the EPI-PHARE Scientific Interest Group, 198,000 French women have these implants and only 30,000 of them, or 15%, have been explanted, knowing that explantation of ESSURE® implants is recommended only in symptomatic patients. A large number of these patients, presenting symptoms, have not yet been treated for an explant.\n\nThe physiopathological mechanism(s) is (are) not yet determined but several arguments are in favor of a dissemination of metallic elements contained in these implants whose accumulation could lead to inflammatory and\u002For allergic and\u002For autoimmune phenomena.\n\nCarrying out a prospective study with long-term longitudinal follow-up appears essential to precisely assess the degree of improvement in the symptoms and quality of life of these patients, determine the most appropriate surgical techniques, and understand the pathophysiological mechanisms that may result in the implementation of specific treatments and relevant markers. From a surgical point of view, there is a real risk of fracture of implants whatever the type of intervention performed: study the biomechanical properties of implants with a view to characterizing their behavior to mechanical rupture but also their thermal resistance in an objective manner seems essential to limit the risk of fracture and help to inform the patient about the surgical technique proposed for explantation. From a biological point of view, the dosage of the metallic elements constituting ESSURE® implants and potentially toxic ones could make it possible to objectify the release of these metallic elements in the body. Analysis of pro-inflammatory cytokines, micro-RNAs (miRNA), quantitative analysis of inflammatory pathway messenger ribonucleic acid (mRNAs) (NanoString technology) and analysis of neuroinflammation by functional imaging should make it possible to explore potential pathophysiological mechanisms. This study responds to a significant request from patient associations.",[26,65],"Contraceptive Device; Complications",[67,68,69],"Essure implant","Contraceptive implant","Symptoms","2026-04-09",{"date":72,"type":40},"2026-04-13",{"date":74,"type":40},"2025-02-17",{"date":76,"type":20},"2037-02-17",{"name":78,"class":47},"Hospices Civils de Lyon",10,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":15,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":48},"100628017","influence-of-zirconia-abutments-on-peri-implant-tissues-in-single-tooth-restorations-100628017","NCT07456163","Influence of Zirconia Abutments on Peri-Implant Tissues in Single-Tooth Restorations","Potential Influence of Pre-fabricated and Customized Anatomical Zirconia Abutments in the Peri-implant Region for Single-tooth Implant-supported Prosthetic Restorations","Inclusion Criteria:\n\n1. Individuals aged 18 years or older;\n2. Participants in the Master's Thesis entitled: \"Dimensional Changes Following Different Alveolar Preservation Protocols in Posterior Regions: A Randomized Controlled Study\";\n3. Patients with implants and healing abutments from Bionnovation Biomedical in place at the time of prosthetic rehabilitation;\n4. Implants without surrounding bone loss;\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Patients with uncontrolled systemic diseases;\n2. Pregnant or lactating women;\n3. Smokers or former smokers;\n4. Undergoing orthodontic treatment;\n5. Using medications that interfere with bone healing, such as those for osteoporosis and bisphosphonates;\n6. Implants with bone loss or failed implants.","18 Years","70 Years",{"count":90,"type":20},71,[23],"Objectives:\n\nTo compare the influence of pre-fabricated titanium abutments and customized milled zirconia abutments on implant biocompatibility and the peri-implant region, as well as on radiographic bone loss and oral health-related quality of life.\n\nDetailed Methodology:\n\nThis study is a randomized controlled clinical trial designed to evaluate the biological and clinical behavior of standardized titanium abutments compared with customized anatomical zirconia abutments in single implant-supported posterior restorations. The present investigation represents the prosthetic phase of a previously conducted randomized clinical trial that evaluated dimensional changes following different alveolar preservation protocols in posterior regions (CAAE: 59208422.8.0000.5418). In the previous phase, participants underwent tooth extraction and alveolar preservation procedures, followed by implant placement with Morse Taper (CM) implants (Biomorse XP, Bionnovation Biomedical) after a six-month healing period. After implant osseointegration, participants eligible for prosthetic rehabilitation will be randomly allocated to one of two parallel groups using a computer-generated randomization sequence (Sealedenvelope.com). The allocation ratio will be 1:1. Sample size calculation was performed using GPower software to ensure adequate statistical power. The intervention consists of prosthetic rehabilitation with either standardized titanium abutments (TiB group) or customized anatomical zirconia abutments (ZiT group), both supporting single zirconia crowns in posterior regions. All prosthetic and laboratory procedures will follow standardized clinical protocols. Clinical and laboratory assessments will be conducted at prosthesis delivery (baseline) and at 1-, 3-, 6-, and 12-month follow-up visits. Data collection will include peri-implant crevicular fluid (PICF) and biofilm sampling for biomolecular analysis, comprehensive periodontal clinical parameters, measurement of keratinized mucosa thickness, standardized periapical radiographs for marginal bone level assessment, and intraoral digital scanning for volumetric and soft tissue analysis. The primary objective is to compare peri-implant tissue stability and biological response between titanium and zirconia abutments. Secondary outcomes include clinical parameters, marginal bone level changes, and soft tissue dimensional stability over a 12-month follow-up period. This study aims to contribute to the understanding of how abutment material and design may influence peri-implant health and long-term tissue stability in posterior implant-supported restorations.",[94,26,95],"Peri-Implant Health","Prosthesis and Implants",[97,98,99,100],"Dental Prosthesis","Connection, Dental Implant-Abutment","Dental Porcelain","Biofilm","2026-03-13",{"date":103,"type":40},"2026-03-17",{"date":105,"type":40},"2025-04-30",{"date":107,"type":20},"2027-12-01",{"name":109,"class":47},"University of Campinas, Brazil",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":15,"sex":57,"minAge":87,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100418616","phase-3-local-antibiotics-for-breast-implants-100418616","NCT04731025","Local Antibiotics for Breast Implants","Prophylactic Treatment of Breast Implants With a Solution of Gentamicin, Vancomycin and Cefazolin Antibiotics for Women Undergoing Breast Reconstructive Surgery: a Randomized Controlled Trial (The BREAST-AB Trial)","BREAST-AB","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Biologically female\n* Signed informed consent\n* Scheduled for breast reconstruction with implants or expanders including:\n\n  1. Immediate or delayed reconstructions\n  2. Bilateral or unilateral reconstructions\n  3. With or without simultaneous flap reconstruction\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast feeding\n* Known allergy towards Vancomycin, Gentamicin and Cefazolin\n* Known anaphylactic reaction towards other beta-lactam antibiotics or aminoglycosides\n* Known allergy towards neomycin\n* Known impaired renal function with GFR \\\u003C 60 mL\u002Fmin\n* Participation in investigational drug trials and projects concerning disinfecting agents in the breast implant cavity\n* Myasthenia Gravis",{"count":119,"type":20},1003,[121],"PHASE3","The BREAST-AB Trial is a multi-center, randomized, double blind, placebo-controlled trial investigating the efficacy of local application of gentamicin, vancomycin and cefazolin in decreasing all-cause implant explantation after breast reconstruction.",[26,124,125,126,127,128,129],"Implant Infection","Implant Site Infection","Implant Capsular Contracture","Implant Site Pocket Infection","Implant Expulsion","Antibiotic Side Effect","2026-02-09",{"date":132,"type":40},"2026-02-12",{"date":134,"type":40},"2021-01-27",{"date":136,"type":20},"2027-08",{"name":138,"class":47},"Mikkel Herly",8,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":15,"sex":16,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":152,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":48},"100467071","pediatric-orthopaedic-implant-safety--efficacy-100467071","NCT05361980","Pediatric Orthopaedic Implant Safety & Efficacy","Global Pediatric Orthopaedic Implant Safety & Efficacy Clinical Follow-up Program","Global POISE","Inclusion Criteria:\n\n* Patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. Off-label use is strongly discouraged; however, any and all on- and off-label indications for use of the products in this program will be collected and stratified accordingly\n* Patients must be able to adhere to the required length of follow-up for the endpoints of each individual product\n* Informed consent\u002Fassent is required\n\nExclusion Criteria:\n\n* Patients with a demonstrated sensitivity to metals\n* Patients with an inability to follow a post-operative regimen","0 Years","25 Years",{"count":151,"type":20},4000,"2 Years","OBSERVATIONAL","Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity.\n\nGiven the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy.\n\nProspective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).",[156,157,158,159,160,161,26,162,163,164,165],"Fracture","Lengthening; Leg","Orthopedic Disorder","Deformity of Limb","Deformity; Bone","Implant Breakage","Hip Dysplasia","Pediatric ALL","Hip Disease","Hip Dislocation","2025-11-19",{"date":168,"type":40},"2025-11-24",{"date":170,"type":40},"2022-01-06",{"date":172,"type":20},"2029-12",{"name":174,"class":47},"University of British Columbia",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":15,"sex":16,"minAge":87,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":48},"100495317","vertical-soft-tissue-augmentation-with-ctg-vs-adm-100495317","NCT05729607","Vertical Soft Tissue Augmentation With CTG vs ADM","Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial","Inclusion criteria:\n\n* Age ≥ 18 years\n* Periodontally and systemically healthy\n* Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)\n* Presence of single functional dental implant in the anterior with a PSTD\n* Implants diagnosed as healthy (Berglundh et al., 2018)\n\nExclusion criteria are:\n\n* Contraindications for surgery\n* Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing\n* Patients pregnant or attempting to get pregnant (self-reported)\n* Untreated periodontitis\n* Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)\n* Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded\n* History of soft tissue grafting at the implant site within the last 6 months","99 Years",{"count":184,"type":20},28,[23],"The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative",[26],"2025-09-12",{"date":190,"type":40},"2025-09-18",{"date":192,"type":40},"2023-05-26",{"date":194,"type":20},"2027-11-27",{"name":196,"class":47},"Harvard Medical School (HMS and HSDM)",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":15,"sex":57,"minAge":87,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":48},"100566031","a-novel-surgical-irrigation-solution-in-post-mastectomy-reconstruction-evaluating-xperience-100566031","NCT06649890","A Novel Surgical Irrigation Solution in Post-Mastectomy Reconstruction: Evaluating Xperience™","A Randomized Control Trial Evaluating the Efficacy of Xperience™ Surgical Irrigation Solution Versus Dilute Povidone-Iodine in Preventing Surgical Site Infections and Improving Postoperative Outcomes in Implant-Based Breast Reconstruction","Inclusion Criteria:\n\n* Older than 18 years old\n* Willing to comply with all study-related procedures\n* Available for the duration of the study\n* Participants undergoing double mastectomy surgery followed by one of the following: (1) Immediate reconstruction with tissue expander placement, (2) Delayed reconstruction with tissue expander or implant placement, (3) Immediate reconstruction with implant placement, (4) Second-stage reconstruction with tissue expander to implant exchange\n\nExclusion Criteria:\n\n* Participants unable to participate in follow-up visits\n* Participants undergoing unilateral mastectomy\n* Tissue expanders placed by a surgeon outside of the UNC Chapel Hill Hospital System\n* Undergoing autologous reconstruction\n* Participant is unable to provide signed and dated informed consent\n* Unwilling or unable to comply with all study-related procedures.\n* Known history of sensitivity or allergic reaction to any of the components of the Xperience™ irrigation solution or dilute povidone-iodine irrigation\n* Participant with any conditions that would be a contraindication to receiving surgery such as contraindications to general anesthesia\n* Pregnant, planning to become pregnant or breast feeding participants\n* Individuals providing informed consent with any mental impairment or condition that would make them unable to properly consent without use of legally authorized representative (LAR) or additional participant protections.\n* Incarcerated participants",{"count":205,"type":20},224,[23],"Goal of the Clinical Trial:\n\nThe purpose of this clinical trial is to learn whether Xperience™ surgical irrigation solution is more effective than a standard dilute povidone-iodine solution in reducing surgical site infections (SSIs) following implant-based breast reconstruction in female patients, aged 18 and older. It will also assess the safety and overall surgical outcomes when using Xperience™ compared to povidone-iodine.\n\nMain Questions the Study Aims to Answer:\n\n* Does the use of Xperience™ decrease the incidence of surgical site infections compared to povidone-iodine?\n* What are the differences in the rates of premature implant removal due to infection between patients treated with Xperience™ and those treated with povidone-iodine?\n* Are there fewer post-surgical complications with Xperience™ compared to povidone-iodine?\n\nStudy Design:\n\nParticipants in this study will be randomly assigned to receive either Xperience™ or a dilute povidone-iodine solution during their bilateral implant-based breast reconstruction. Only the research team will know which irrgiation is given- the participant will not know.\n\nParticipant Will:\n\n* Undergo the surgical procedure using one of the two irrigation solutions.\n* Receive regular post-operative check-ups to monitor for signs of infection and other complications.\n* Have data collected on any post-surgical complications, the necessity for early implant removal, and overall surgical outcomes.",[209,210,124,26],"Surgical Site Infection","Surgical Complication","2025-08-06",{"date":213,"type":40},"2025-08-07",{"date":215,"type":40},"2025-06-30",{"date":217,"type":20},"2028-06-30",{"name":219,"class":47},"University of North Carolina, Chapel Hill",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":48},"100555730","characterizing-the-inflammation-around-dental-implants-bacterial-infection-hypersensitivity-or-both-100555730","NCT06515886","Characterizing the Inflammation Around Dental Implants: Bacterial Infection, Hypersensitivity or Both?","Inclusion Criteria:\n\n* Received at least one functional implant (implant restored with a prothesis);\n* Did not receive peri-implant mucositis and peri-implantitis treatment in the past three months.\n\nExclusion criteria:\n\n* Dental records with incomplete information;\n* Individuals with a weak immune system or chronic disease such as diabetes, heart, lung or kidney disease;\n* Pregnant women;\n* Individuals undergoing orthodontic therapy and those who have oral piercing.\n* History of diseases that modify or suppress the immune and inflammatory response, including rheumatoid arthritis, diabetes, lupus, and inflammatory bowel disease and metastatic cancer;\n* Taking medications that cause antiresorptive osteonecrosis of the jaw (including any dose of intravenous bisphosphonates, oral bisphosphonate intake for more than three years, receptor activator of nuclear factor kappa-B ligand inhibitors, or antiangiogenic medications);\n* Taking medications known to induce gingival hyperplasia including anticonvulsants, immunosuppressants, or calcium channel blockers;\n* Taking steroid medications, systemic or local antibiotics in the last three months (as this may affect the interleukins activity);\n* Received radiation therapy to the head and neck or chemotherapy;\n* Received treatment to manage an inflamed implant, including management of peri-implantitis and peri-implant mucositis in the last three months.",{"count":227,"type":20},40,"The use of titanium dental implants has become a common modern treatment to restore teeth. Although the success rate of dental implants is high, inflammation around the dental implant still occurs. The current study will investigate if the inflammation around the implant is due to bacterial infection, hypersensitivity or both.",[230,26,125,231],"Dental Implant Failed","Implant Site Reaction",[233,234,235,236,237,238],"Dental implant","Peri-implant inflammation","Inflammatory mediators","Bacterial infection","Hypersensitivity","peri-implantitis","2024-07-19",{"date":241,"type":40},"2024-07-23",{"date":243,"type":40},"2022-09-22",{"date":245,"type":20},"2025-12-01",{"name":247,"class":47},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":15,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":255,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":267,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100555023","optimizing-surgical-and-prosthetic-workflow-for-implant-supported-ear-and-nose-prostheses-with-early-loading-and-distant-prosthesis-fabrication-a-prospective-cohort-study-100555023","NCT06506695","Optimizing Surgical and Prosthetic Workflow for Implant-supported Ear and Nose Prostheses With Early Loading and Distant Prosthesis Fabrication: A Prospective Cohort Study","Inclusion Criteria:\n\n* Adult patients with a facial defect in the nasal and\u002For temporal area that will not be repaired with autologous tissue;\n* Adult patients receiving oncological resection or trauma resulting in a facial defect in the nose and\u002For ear that will not be repaired with autologous tissue;\n* Patients who can come to the hospital every week for 6 weeks.\n\nExclusion Criteria:\n\n* Patients with insufficient bone mass for implant placement\n* Patients who cannot come to the hospital for weekly follow-ups\n* Patients that wish an autologous reconstruction\n* Patient is unable to tolerate general anesthesia",{"count":79,"type":20},[23],"Facial defects created by trauma, oncological procedures or congenital conditions can be repaired with ear, nose and\u002For eye prostheses. These are fixed on intraosseous implants placed in the temporal, nasal and orbital bone. To date, an osseointegration period of 3-6 months is maintained after which the implants are loaded.\n\nThis study aims to achieve two goals:\n\n1. To load the implants with a nose or ear prosthesis within one month (preferably \\\u003C3 weeks). Patients with an orbital prosthesis will not be recruited. In other words, an optimization of an existing protocol will be investigated. The quality of life of the patients as well as possible complications of the implants will be investigated.\n2. Because of the short time between the surgery and the placement of the prosthesis, the prosthesis will be fabricated remotely. This means that the patient will not have to travel to the prosthetist. The feasibility and aesthetics will be analyzed through questionnaires for the patient.",[258,26],"Facial Deformity",[260,261,262,263,264,265,266],"Facial defect","Facial Prosthesis","Ear prosthesis","Nose prosthesis","Craniofacial implant","Anaplastology","Prosthesis fabrication","NOT_YET_RECRUITING","2024-07-16",{"date":270,"type":40},"2024-07-17",{"date":272,"type":20},"2024-09-15",{"date":274,"type":20},"2025-12-31",{"name":276,"class":47},"University Hospital, Ghent",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":48},"100552806","assessment-of-implants-placed-in-consolidated-graft-with-different-bone-drills-100552806","NCT06477874","Assessment of Implants Placed in Consolidated Graft With Different Bone Drills.","ASSESSMENT OF DENTAL IMPLANTS PLACED IN MANDIBULAR CONSOLIDATED ILIAC-CREST BONE GRAFTS USING DENSAH BURS VERSUS THE STANDARD DRILLS (A Randomized Controlled Trial)","Inclusion Criteria:\n\n1. Patients of both sexes with an age range of 18-55 years.\n2. Patients subjected to a successful iliac crest mandibular bone graft after segmental mandibular resection.\n3. A minimal ridge height of ten millimeters and a ridge width of seven millimeters.\n4. Healthy soft tissue coverage, with a reasonable interaction space.\n\nExclusion Criteria:\n\n1. Clinical or radiographic signs of graft infection, rejection, or massive resorption.\n2. The previous exposure to radiotherapy or chemotherapy.\n3. Any systemic disease that would affect bone healing or implant osseointegration.","55 Years",{"count":5,"type":20},[23],"The anterior iliac crest is a popular source of bone harvest. However, when fused to the intramembranous jaw bones, it yields low-density bones that qualitatively and quantitatively endanger the fixture's stability.\n\nIn 1994, Summers first documented using the bone-condensing approach to improve the primary stability of dental implants.\n\nThis study aims to determine whether osseodensifying the consolidated mandibular bone grafts will improve implant stability and marginal bone loss",[26,289],"Bone Graft; Mechanical Complications",[291,292,293],"Bone graft","Iliac crest","Implant stability","2024-06-26",{"date":296,"type":40},"2024-06-27",{"date":298,"type":40},"2024-06-09",{"date":300,"type":20},"2025-04-01",{"name":302,"class":47},"Beni-Suef University",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":48},"100550493","survival-rate-of-2-implant-supported-short-span-fixed-partial-dentures-100550493","NCT06447792","Survival Rate of 2 Implant-supported Short-span Fixed Partial Dentures","Survival Rate of 2 Implant-supported Short-span Fixed Partial Dentures in the Anterior Mandible: A Retrospective Study","Inclusion Criteria:\n\n* fully dentulous people over 25 who complained of the mobility of 4 mandibular incisor teeth, or partially dentulous people who missed 2 mandibular central incisor teeth and had periodontally affected the neighboring lateral incisor teeth.\n* These individuals were subsequently treated with 2 implants supporting FPDs and following a delayed, progressive, or immediate loading protocol\n* Class 0 or 1 bone defects after tooth extraction, were only included in the study\n* The medical records included data regarding implant type, width, and length, surgical procedure, annual hygienist treatments, radiographs, and implant insertion date\n\nExclusion Criteria:\n\n* had less than 1 years of follow-up, had incomplete restorative or surgical data, had non-diagnostic radiographs, had more or less than 4 unit fixed partial denture\n* patients did not present for annual follow-up visits to evaluate oral hygiene measures or treat mechanical or technical complications.\n* Individuals with bone defects class 2, 3, 4, or 5 after mandibular lateral incisor tooth extraction were also excluded.","65 Years",{"count":312,"type":20},60,"Implant supported superstructure is necessary for long term success and durability of the implant itself in terms of stresses distribution and fracture strength capability.1 Stresses falling on an implant are too much greater than those applied on a tooth structure with a periodontal ligament offering a degree of elasticity. The important mechanical and physical properties of materials used for the fabrication of dental prostheses include adequate flexural and tensile strength and modulus of elasticity, maximum fracture resistance, optimal bond strength and adequate polishability.",[26,315],"Bone Loss","2024-06-02",{"date":318,"type":40},"2024-06-07",{"date":320,"type":40},"2024-02-01",{"date":322,"type":20},"2024-08-20",{"name":324,"class":47},"Menoufia University",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":15,"sex":16,"minAge":331,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":21,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":48},"100539734","clinical-and-radiographic-evaluation-of-immediate-implant-placement-using-osseodensification-versus-traditional-drilling-protocol-100539734","NCT06307691","Clinical and Radiographic Evaluation of Immediate Implant Placement Using Osseodensification Versus Traditional Drilling Protocol","Inclusion Criteria:\n\n* Patients in need of extraction of a single, unrestorable tooth in the esthetic zone including maxillary anteriors and premolars\n* Age range between 20-60 years old\n* An intact buccal plate of bone after extraction\n* Medically free patients (Brightman. 1994)\n* Cooperative patients willing to follow up for the duration of the study.\n\nExclusion Criteria:\n\n* Acute infection in the implant site\n* Patients incapable of maintaining oral hygiene\n* Pregnant and nursing female patients\n* Smokers (more than 5 cigarettes per day)\n* A habit of bruxism\n* Periodontal disease\n* Subjects who have a systemic disease which affects bone healing as diabetes\n* Use of bone metabolism medicines; (Bisphosphonates) .","20 Years","60 Years",{"count":334,"type":20},26,[23],"For the purpose of the study, patients will be divided into two groups, i.e., Group A and Group B. In Group (A), 14 immediate implants will be placed using traditional drilling technique, while in Group (B), 14 immediate implants will be placed using OD drilling technique Osseodensification is a system for implant osteotomy preparation, it compresses the cancellous bone around the revolving drills. It largely improves low bone volume by physically increasing the interlocking between the bone and the implant surface. The Densah burs enhances bone density while generating the least amount of heat.\n\nTraditional oversized drilling is the regular manufacturer recommended technique of drilling. It functions by cutting the bone during osteotomy preparation by sharp fluted drills. The undersizing of the preparation allows the implant to partially compact the bone during insertion.\n\nThe objective of the current study is to compare between osseodensification drilling protocol versus traditional undersized drilling protocol in immediate implant placement in anterior maxillary region in terms of implant stability.",[26],[293],"2024-03-16",{"date":341,"type":40},"2024-03-19",{"date":343,"type":40},"2024-03-06",{"date":345,"type":20},"2026-12-20",{"name":347,"class":47},"Cairo University"]